FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034291632> ?p ?o ?g. }

• W2034291632 endingPage "278" @default.
• W2034291632 startingPage "273" @default.
• W2034291632 abstract "The aim of this study was to analyze FIGO Stage IIIc endometrial cancer (EC) patients to better define clinicopathologic associations, patterns of failure, and survival.Charts were abstracted from EC patients with lymph node metastasis from 1989 to 1998. Data on clinicopathologic variables, adjuvant treatment, site of first recurrence, and survival were collected. Associations between variables were tested by chi(2) and Wilcoxon rank sums. Survival analyses were performed by the Kaplan-Meier method, and multiple regression analysis was done by the Cox proportional hazards model.From 607 EC patients evaluated, 47 (8%) were identified with FIGO Stage IIIc disease. All 47 underwent hysterectomy and pelvic lymph node (PLN) sampling, and 42/47 had para-aortic lymph node (PALN) sampling. Stage IIIc disease was defined by positive PLN alone in 38%, positive PLN and PALN in 41%, and positive PALN alone in 17%. Twelve of 47 also had positive peritoneal cytology and/or adnexal metastases. Grade III tumors were present in 56% and >50% myometrial invasion in 61%. No association between depth of invasion (DOI) and grade was seen, however. Nearly 1/3 of cases had papillary serous or clear cell histology. Postoperative adjuvant treatment included whole abdominal radiation (36%), pelvic radiation with (19%) and without (17%) extended field, chemotherapy (17%), and oral progestins (11%). The 3-year and 5-year survival estimates for all patients were 77 and 65%, respectively. At a median follow-up of 37 months, 5 patients are alive with disease, and 10 are dead of disease. A distant site of first recurrence was most common (21%), followed by pelvic failure (9%). Only 1 patient has had an abdominal recurrence. Univariate predictors of survival included age, DOI, and extranodal disease, but not grade, histology, or PALN involvement. For the 12 patients with nodal disease and positive cytology and/or adnexa, 3-year survival was 39% versus 93% for those patients without evidence of extranodal disease. In a multivariate analysis only DOI was an independent predictor of survival (P = 0.03).Once lymph node involvement occurs, the importance of additional extranodal disease increases. Consideration of substaging Stage IIIc patients based on positive adnexa or cytology is supported by the data. The extent which adjuvant treatments contributed to the 77% 3-year survival remains to be defined. The patterns of failure suggest a possible role for combined modalities in future treatments." @default.
• W2034291632 created "2016-06-24" @default.
• W2034291632 creator A5008466254 @default.
• W2034291632 creator A5021105630 @default.
• W2034291632 creator A5053990407 @default.
• W2034291632 creator A5061736280 @default.
• W2034291632 creator A5084542258 @default.
• W2034291632 creator A5088842172 @default.
• W2034291632 date "2001-05-01" @default.
• W2034291632 modified "2023-09-27" @default.
• W2034291632 title "Analysis of FIGO Stage IIIc Endometrial Cancer Patients" @default.
• W2034291632 cites W1975654270 @default.
• W2034291632 cites W1980259770 @default.
• W2034291632 cites W1982937278 @default.
• W2034291632 cites W1998222452 @default.
• W2034291632 cites W2002991620 @default.
• W2034291632 cites W2007160797 @default.
• W2034291632 cites W2016558284 @default.
• W2034291632 cites W2019897392 @default.
• W2034291632 cites W2028517400 @default.
• W2034291632 cites W2031422053 @default.
• W2034291632 cites W2032496182 @default.
• W2034291632 cites W2046569169 @default.
• W2034291632 cites W2047815688 @default.
• W2034291632 cites W2077679369 @default.
• W2034291632 cites W2092931831 @default.
• W2034291632 cites W2123927174 @default.
• W2034291632 cites W2150051278 @default.
• W2034291632 cites W2314753133 @default.
• W2034291632 doi "https://doi.org/10.1006/gyno.2001.6157" @default.
• W2034291632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11330962" @default.
• W2034291632 hasPublicationYear "2001" @default.
• W2034291632 type Work @default.
• W2034291632 sameAs 2034291632 @default.
• W2034291632 citedByCount "110" @default.
• W2034291632 countsByYear W20342916322012 @default.
• W2034291632 countsByYear W20342916322013 @default.
• W2034291632 countsByYear W20342916322014 @default.
• W2034291632 countsByYear W20342916322015 @default.
• W2034291632 countsByYear W20342916322016 @default.
• W2034291632 countsByYear W20342916322017 @default.
• W2034291632 countsByYear W20342916322018 @default.
• W2034291632 countsByYear W20342916322019 @default.
• W2034291632 countsByYear W20342916322020 @default.
• W2034291632 countsByYear W20342916322021 @default.
• W2034291632 countsByYear W20342916322022 @default.
• W2034291632 countsByYear W20342916322023 @default.
• W2034291632 crossrefType "journal-article" @default.
• W2034291632 hasAuthorship W2034291632A5008466254 @default.
• W2034291632 hasAuthorship W2034291632A5021105630 @default.
• W2034291632 hasAuthorship W2034291632A5053990407 @default.
• W2034291632 hasAuthorship W2034291632A5061736280 @default.
• W2034291632 hasAuthorship W2034291632A5084542258 @default.
• W2034291632 hasAuthorship W2034291632A5088842172 @default.
• W2034291632 hasConcept C121608353 @default.
• W2034291632 hasConcept C126322002 @default.
• W2034291632 hasConcept C141071460 @default.
• W2034291632 hasConcept C143998085 @default.
• W2034291632 hasConcept C146357865 @default.
• W2034291632 hasConcept C151730666 @default.
• W2034291632 hasConcept C2777088508 @default.
• W2034291632 hasConcept C2778740770 @default.
• W2034291632 hasConcept C2779013556 @default.
• W2034291632 hasConcept C2779494336 @default.
• W2034291632 hasConcept C2780824555 @default.
• W2034291632 hasConcept C2780849966 @default.
• W2034291632 hasConcept C29456083 @default.
• W2034291632 hasConcept C50382708 @default.
• W2034291632 hasConcept C66339696 @default.
• W2034291632 hasConcept C71924100 @default.
• W2034291632 hasConcept C86803240 @default.
• W2034291632 hasConcept C90924648 @default.
• W2034291632 hasConceptScore W2034291632C121608353 @default.
• W2034291632 hasConceptScore W2034291632C126322002 @default.
• W2034291632 hasConceptScore W2034291632C141071460 @default.
• W2034291632 hasConceptScore W2034291632C143998085 @default.
• W2034291632 hasConceptScore W2034291632C146357865 @default.
• W2034291632 hasConceptScore W2034291632C151730666 @default.
• W2034291632 hasConceptScore W2034291632C2777088508 @default.
• W2034291632 hasConceptScore W2034291632C2778740770 @default.
• W2034291632 hasConceptScore W2034291632C2779013556 @default.
• W2034291632 hasConceptScore W2034291632C2779494336 @default.
• W2034291632 hasConceptScore W2034291632C2780824555 @default.
• W2034291632 hasConceptScore W2034291632C2780849966 @default.
• W2034291632 hasConceptScore W2034291632C29456083 @default.
• W2034291632 hasConceptScore W2034291632C50382708 @default.
• W2034291632 hasConceptScore W2034291632C66339696 @default.
• W2034291632 hasConceptScore W2034291632C71924100 @default.
• W2034291632 hasConceptScore W2034291632C86803240 @default.
• W2034291632 hasConceptScore W2034291632C90924648 @default.
• W2034291632 hasIssue "2" @default.
• W2034291632 hasLocation W20342916321 @default.
• W2034291632 hasLocation W20342916322 @default.
• W2034291632 hasOpenAccess W2034291632 @default.
• W2034291632 hasPrimaryLocation W20342916321 @default.
• W2034291632 hasRelatedWork W1992129982 @default.
• W2034291632 hasRelatedWork W2491745425 @default.
• W2034291632 hasRelatedWork W2613497393 @default.

• next